Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Latent Warheads for Targeted Cancer Therapy: Design and Synthesis of pro-Pyrrolobenzodiazepines and Conjugates.

Vlahov IR, Qi L, Kleindl PJ, Santhapuram HK, Felten A, Parham GL, Wang K, You F, Vaughn JF, Hahn SJ, Klein HF, Vetzel M, Reddy JA, Nelson M, Nicoson J, Leamon CP.

Bioconjug Chem. 2017 Dec 20;28(12):2921-2931. doi: 10.1021/acs.bioconjchem.7b00476. Epub 2017 Dec 6.

PMID:
29211454
2.

Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.

Leamon CP, Reddy JA, Vlahov IR, Dorton R, Bloomfield A, Vetzel M, Klein PJ, Westrick E, Xu LC, Wang Y.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1151-1160. doi: 10.1007/s00280-017-3311-z. Epub 2017 Apr 27.

PMID:
28451831
3.

High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.

Guertin AD, O'Neil J, Stoeck A, Reddy JA, Cristescu R, Haines BB, Hinton MC, Dorton R, Bloomfield A, Nelson M, Vetzel M, Lejnine S, Nebozhyn M, Zhang T, Loboda A, Picard KL, Schmidt EV, Dussault I, Leamon CP.

Mol Cancer Ther. 2016 Aug;15(8):1998-2008. doi: 10.1158/1535-7163.MCT-15-0950. Epub 2016 Jun 2.

4.

Development and validation of a UPLC-MS/MS method for the novel folate-targeted small molecule drug conjugate EC1456 and its metabolites in tumor homogenates from mice.

Rao SI, Pugh M, Nelson M, Reddy JA, Klein PJ, Leamon CP.

J Pharm Biomed Anal. 2016 Apr 15;122:148-56. doi: 10.1016/j.jpba.2016.01.049. Epub 2016 Jan 25.

PMID:
26855286
5.

The folate receptor as a rational therapeutic target for personalized cancer treatment.

Assaraf YG, Leamon CP, Reddy JA.

Drug Resist Updat. 2014 Oct-Dec;17(4-6):89-95. doi: 10.1016/j.drup.2014.10.002. Epub 2014 Oct 8. Review.

PMID:
25457975
6.

Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.

Leamon CP, Vlahov IR, Reddy JA, Vetzel M, Santhapuram HK, You F, Bloomfield A, Dorton R, Nelson M, Kleindl P, Vaughn JF, Westrick E.

Bioconjug Chem. 2014 Mar 19;25(3):560-8. doi: 10.1021/bc400441s. Epub 2014 Mar 11.

PMID:
24564229
7.

Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.

Reddy JA, Dorton R, Bloomfield A, Nelson M, Vetzel M, Guan J, Leamon CP.

Clin Cancer Res. 2014 Apr 15;20(8):2104-14. doi: 10.1158/1078-0432.CCR-13-2423. Epub 2014 Jan 15.

8.

Targeting folate receptors to treat invasive urinary bladder cancer.

Dhawan D, Ramos-Vara JA, Naughton JF, Cheng L, Low PS, Rothenbuhler R, Leamon CP, Parker N, Klein PJ, Vlahov IR, Reddy JA, Koch M, Murphy L, Fourez LM, Stewart JC, Knapp DW.

Cancer Res. 2013 Jan 15;73(2):875-84. doi: 10.1158/0008-5472.CAN-12-2101. Epub 2012 Nov 29.

9.

Acid mediated formation of an N-acyliminium ion from tubulysins: a new methodology for the synthesis of natural tubulysins and their analogs.

Vlahov IR, Wang Y, Vetzel M, Hahn S, Kleindl PJ, Reddy JA, Leamon CP.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6778-81. doi: 10.1016/j.bmcl.2011.09.041. Epub 2011 Sep 17.

PMID:
21974954
10.

Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.

Leamon CP, Reddy JA, Klein PJ, Vlahov IR, Dorton R, Bloomfield A, Nelson M, Westrick E, Parker N, Bruna K, Vetzel M, Gehrke M, Nicoson JS, Messmann RA, LoRusso PM, Sausville EA.

J Pharmacol Exp Ther. 2011 Feb;336(2):336-43. doi: 10.1124/jpet.110.175109. Epub 2010 Oct 26.

11.

Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.

Müller C, Reddy JA, Leamon CP, Schibli R.

Mol Pharm. 2010 Apr 5;7(2):597-604. doi: 10.1021/mp900296k.

PMID:
20199053
12.

In vivo structural activity and optimization studies of folate-tubulysin conjugates.

Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, Westrick E, Klein PJ, Wang Y, Vlahov IR, Leamon CP.

Mol Pharm. 2009 Sep-Oct;6(5):1518-25. doi: 10.1021/mp900086w.

PMID:
19630399
13.

Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.

Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I.

Cancer Res. 2008 Dec 1;68(23):9839-44. doi: 10.1158/0008-5472.CAN-08-2341.

14.

Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.

Leamon CP, Reddy JA, Dorton R, Bloomfield A, Emsweller K, Parker N, Westrick E.

J Pharmacol Exp Ther. 2008 Dec;327(3):918-25. doi: 10.1124/jpet.108.143206. Epub 2008 Sep 12.

15.

Preclinical antitumor activity of a novel folate-targeted dual drug conjugate.

Leamon CP, Reddy JA, Vlahov IR, Westrick E, Dawson A, Dorton R, Vetzel M, Santhapuram HK, Wang Y.

Mol Pharm. 2007 Sep-Oct;4(5):659-67. Epub 2007 Sep 18.

PMID:
17874843
16.

Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.

Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, Leamon CP.

Cancer Res. 2007 Jul 1;67(13):6376-82.

17.

An assembly concept for the consecutive introduction of unsymmetrical disulfide bonds: synthesis of a releasable multidrug conjugate of folic acid.

Vlahov IR, Santhapuram HK, Wang Y, Kleindl PJ, You F, Howard SJ, Westrick E, Reddy JA, Leamon CP.

J Org Chem. 2007 Aug 3;72(16):5968-72. Epub 2007 Jun 29.

PMID:
17602528
18.

Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.

Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, Vetzel M.

Int J Cancer. 2007 Oct 1;121(7):1585-92.

19.

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.

Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP.

Cancer Res. 2007 May 1;67(9):4434-42.

20.

Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice.

Lu Y, Xu LC, Parker N, Westrick E, Reddy JA, Vetzel M, Low PS, Leamon CP.

Mol Cancer Ther. 2006 Dec;5(12):3258-67.

21.

Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate.

Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M, Westrick E.

Bioconjug Chem. 2006 Sep-Oct;17(5):1226-32.

PMID:
16984132
22.

Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.

Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP.

Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36. Epub 2005 Dec 6.

PMID:
16331500
23.

Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.

Leamon CP, Reddy JA, Vlahov IR, Vetzel M, Parker N, Nicoson JS, Xu LC, Westrick E.

Bioconjug Chem. 2005 Jul-Aug;16(4):803-11.

PMID:
16029021
24.

Targeting therapeutic and imaging agents to folate receptor positive tumors.

Reddy JA, Allagadda VM, Leamon CP.

Curr Pharm Biotechnol. 2005 Apr;6(2):131-50. Review.

PMID:
15853692
25.

Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.

Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS.

Mol Pharmacol. 2004 Dec;66(6):1406-14. Epub 2004 Sep 15.

26.

Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors.

Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP.

J Nucl Med. 2004 May;45(5):857-66.

27.

Folate-targeted chemotherapy.

Leamon CP, Reddy JA.

Adv Drug Deliv Rev. 2004 Apr 29;56(8):1127-41. Review.

PMID:
15094211
28.

Dapsone-induced acute pancreatitis.

Jha SH, Reddy JA, Dave JK.

Ann Pharmacother. 2003 Oct;37(10):1438-40.

PMID:
14519046
29.

Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical.

Leamon CP, Parker MA, Vlahov IR, Xu LC, Reddy JA, Vetzel M, Douglas N.

Bioconjug Chem. 2002 Nov-Dec;13(6):1200-10.

PMID:
12440854
30.

Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors.

Reddy JA, Abburi C, Hofland H, Howard SJ, Vlahov I, Wils P, Leamon CP.

Gene Ther. 2002 Nov;9(22):1542-50.

31.

Folate-targeted gene transfer in vivo.

Hofland HE, Masson C, Iginla S, Osetinsky I, Reddy JA, Leamon CP, Scherman D, Bessodes M, Wils P.

Mol Ther. 2002 Jun;5(6):739-44.

32.

Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs.

Turk MJ, Reddy JA, Chmielewski JA, Low PS.

Biochim Biophys Acta. 2002 Feb 10;1559(1):56-68.

33.

Retargeting of viral vectors to the folate receptor endocytic pathway.

Reddy JA, Clapp DW, Low PS.

J Control Release. 2001 Jul 6;74(1-3):77-82.

PMID:
11489485
34.

Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation.

Reddy JA, Low PS.

J Control Release. 2000 Feb 14;64(1-3):27-37.

PMID:
10640643
35.

Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy.

Reddy JA, Dean D, Kennedy MD, Low PS.

J Pharm Sci. 1999 Nov;88(11):1112-8.

PMID:
10564057
36.

Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells.

Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS.

Blood. 1999 Jun 1;93(11):3940-8.

37.

Folate-mediated targeting of therapeutic and imaging agents to cancers.

Reddy JA, Low PS.

Crit Rev Ther Drug Carrier Syst. 1998;15(6):587-627. Review.

PMID:
9883391
38.

A RETROSPECTIVE STUDY OF TRAUMATIC TYMPANIC MEMBRANE PERFORATIONS-OUR EXPERIENCE.

Galagali JR, Reddy JA, Nanda SK.

Med J Armed Forces India. 1998 Jul;54(3):287. doi: 10.1016/S0377-1237(17)30572-5. Epub 2017 Jun 26. No abstract available.

Supplemental Content

Loading ...
Support Center